Multiple morbidities in pregnancy: Time for
research, innovation, and action by Beeson, James G. et al.
EDITORIAL
Multiple morbidities in pregnancy: Time for
research, innovation, and action
James G. BeesonID
1,2,3*, Caroline S. E. HomerID1,4, Christopher Morgan1,2,3,
Clara Menendez5,6
1 Burnet Institute, Melbourne, Victoria, Australia, 2 Central Clinical School and School of Public Health and
Preventive Medicine, Monash University, Melbourne, Australia, 3 Department of Medicine and Melbourne
School of Population and Global Health, University of Melbourne, Melbourne, Australia, 4 Centre for
Midwifery, Child and Family Health, Faculty of Health, University of Technology Sydney, Sydney, Australia,
5 Barcelona Institute for Global Health (ISGlobal), Hospital Clinic of Barcelona, Universitat de Barcelona,
Barcelona, Spain, 6 Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique
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Progress indicators in maternal health in many low- and middle-income countries (LMICs)
continue to fall below international standards despite Millennium Development Goal commit-
ments and Sustainable Development Goal (SDG) aspirations [1]. While maternal mortality has
fallen by 44% globally since 1990, many countries will struggle to meet the SDG target of fewer
than 70 maternal deaths per 100,000 live births by 2030 [2]. Despite substantial efforts, globally
over 300,000 women still die each year during pregnancy, childbirth, or the postpartum
period, mostly from preventable causes. The burden of morbidity and mortality is inequitable,
with vulnerable and marginalized populations at greatest risk. Although this burden dispro-
portionately occurs in LMICs, it also affects increasing numbers of women in some high-
income countries [3]. Improved counts of so-called indirect causes highlight the importance of
nonobstetric morbidity during pregnancy, contributing around one-third of maternal deaths
in LMICs [4]. Indirect causes include the effects of infections, noncommunicable diseases
(NCDs), and mental health disorders. These highly prevalent conditions overlap and co-occur
such that many women experience multimorbidity during and around pregnancy [5].
Recognizing multimorbidity as an issue affecting pregnant women
Infectious diseases (such as HIV, malaria, tuberculosis, and sexually transmitted infections
[STIs]) together with NCDs that are increasingly common in LMICs as a result of demo-
graphic, socioeconomic, and environmental changes (cardiovascular disease, diabetes, anemia,
micronutrient deficiencies, hypertension, and mental health challenges) each account for sub-
stantial morbidity in pregnancy; however, the burden of their combination is less well recog-
nized, and the impacts are not well understood. Some co-occurring morbidities have been well
described, such as coinfection with HIV, malaria, or tuberculosis. Curable STIs (syphilis, gon-
orrhea, chlamydia, trichomonas, and others) likely infect about 40% of pregnant women in
sub-Saharan Africa [6], with negative implications for the health of mother and baby. Infec-
tious plus noninfectious multimorbidity is also important, such as malaria with anemia from
nutritional deficiencies and tuberculosis with diabetes [1,5]. In LMIC settings, typically most
pregnant women are anemic and have significant nutritional deficiencies [1,5], which may
have impact on infections and NCDs [7]. Other multimorbidities are likely to have major
impacts but are poorly understood. There is a major knowledge gap for many important co-
occurring diseases and risk factors, especially the interaction of macro- and micronutrient
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deficiencies with infections and other conditions. In addition, poor maternal mental health
has short- and long-term adverse effects on mothers and babies and has a likely impact on the
whole family [8].
Need for research and innovation
Addressing the burden of multimorbidity requires innovation and investment to drive the
development of new tools, interventions, and strategies. We have listed the main priorities for
research and innovation across levels of healthcare in Box 1. Greater research and innovation
are urgently needed to identify common contributing factors and adversely synergistic interac-
tions. Given the increasing burden of NCDs, there is a strong need to understand the interac-
tions between different NCDs, as well as between infections and NCDs, among pregnant
women. Clinical research is needed to test the potential of integrated interventions against
common comorbidities (e.g., malaria and STIs, including HIV). Testing of interventions
should be accompanied by improved surveillance and reporting of multimorbidities and a bet-
ter understanding of the causes of maternal mortality, especially indirect deaths.
Determining pathogenic interactions underlying multimorbidity will be important to guide
new interventions, and it is possible that, at least for some conditions, there may be common
or interacting pathways that could be targeted (e.g., malaria in pregnancy together with under-
nutrition leading to low L-arginine levels can compound fetal growth restriction [9]). The use
of systems biology approaches and application of platform technologies such as genomics, pro-
teomics, and metabolomics may reveal pathogenesis mechanisms and better define processes
to inform interventions and identify biomarkers for diagnostics or risk stratification. It is likely
that there are common root causes and contributors for many conditions, such as low educa-
tion, poverty, conflict and displacement, and fragile or nonfunctional health systems. Research
to build knowledge on long-term consequences of multimorbidities in pregnancy for mothers
and children is a priority to maximize potential health gains. New diagnostics and screening
technologies for conditions that contribute to multimorbidity need to be brought within reach
of LMICs: low cost, easy to use, rapid, and deployable in front-line clinics or community set-
tings. Past examples include rapid diagnostic tests (RDTs) for specific infections, glycometers
for diabetes, and urine test sticks, to name a few. Nucleic acid amplification technologies for
highly sensitive testing of infections or risk factors are becoming simpler to use, more portable,
and cheaper and may offer future solutions [10].
To achieve these advances also requires greater investment by industry and biotech in tech-
nologies and products for maternal health (including diagnostics, therapeutics, vaccines, and
mHealth). Current levels of investment in research and development (R&D) in this field are
very low, with very few new therapeutics, vaccines, or diagnostics for maternal health condi-
tions being licensed in recent decades. Pregnant women are usually excluded from clinical tri-
als of medical products, which has limited their access to the benefits of medical advances.
Public–private partnerships and cofunding or incentive schemes could be used to enhance
R&D investment, as has proven successful in several diseases. We argue that there should be a
wider inclusion of pregnant women in clinical and implementation research; this will provide
pregnancy-specific knowledge and help integrate maternal health into broader health
solutions.
Challenges for health services
Multimorbidity calls for new or enhanced models of care, as well as the application of new
technologies and interventions. Innovative diagnostics and systems research will enable
broader screening of pregnant women for diseases or risk factors, especially diseases that are
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frequently asymptomatic and have major impacts, such as curable STIs, poor nutrition, HIV,
malaria, and others. Multimorbidity also demands more integrated service delivery, providing
quality care that addresses the full spectrum of health needs of each woman; however, current
evidence on how best to integrate pregnancy interventions into primary healthcare or public
health programs, such as immunization programs, is insufficient to guide policy [11]. Also
critical is integration through to postnatal care, which currently has unacceptably low coverage
in LMICs and is typically provided through models that pay little attention to maternal multi-
morbidity [12]. Postnatal visits and even infant immunization visits represent key opportuni-
ties for further screening and follow-up of maternal conditions identified in pregnancy and
childbirth.
Essential and just as urgent is the development and enabling of a sustainable health work-
force that is trained for the challenges posed by multimorbidity. Significant shortages in the
global health workforce, especially midwives and obstetricians, including access to continuing
professional development, severely constrain the system’s capacity to provide quality care.
Quality maternal and newborn care needs an emphasis on accessible and respectful care, pre-
vention, and management of complications within a functional health system [13].
Box 1. Priorities in research and innovation to address
multimorbidities in pregnancy.
1. Understand the major comorbidities, their interactions, cocontributing factors,
and common pathways of diseases that co-occur in pregnancy, as well as interac-
tions between drugs used to treat common conditions
2. Better understand and quantify long-term consequences for children and mothers
of multimorbidity in pregnancy
3. Wider inclusion of pregnant women in clinical research and implementation
studies
4. Develop new tools for diagnosis and screening for multimorbidities that are low
cost, easy to use, and rapid and deployable in clinics and community settings
within the available workforce
5. Develop and test new multimorbidity interventions informed by knowledge of
interactions, common pathways, and root causes
6. Identify health service integration strategies that address multimorbidity in the
antenatal, postnatal, and infancy periods
7. Develop models of care and a health workforce that promote health system–
patient–community partnerships for care and interventions across the spectrum
of reproductive, maternal, and child health
8. Promote greater investment by industry and biotech in technologies and products
for maternal health (including diagnostics, therapeutics, vaccines, and mobile
health [mHealth])
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Conclusion
The burden of multimorbidity in pregnancy, combined with global epidemiological changes
in disease patterns and resource and health system constraints, poses challenges that can best
be addressed by accelerating sustainable improvements in maternal health. Renewed and
strengthened focus, research and innovation, and investment and partnerships to address this
challenge are urgently needed.
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